Jørgen Fischer Ravn
Keine laufenden Positionen mehr
Profil
Jørgen Fischer Ravn worked as a Partner at Reliance A and as VP-Investor Relations & Communications at Bionor Pharma ASA from 2015 to 2016.
Ehemalige bekannte Positionen von Jørgen Fischer Ravn
Unternehmen | Position | Ende |
---|---|---|
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Investor Relations Kontakt | 01.09.2016 |
Reliance A/S
Reliance A/S Miscellaneous Commercial ServicesCommercial Services Reliance A/S provides business consulting services. The company also provides services to the public and initial public offering companies. It offers advices in the areas such as investor relations, corporate finance, equity research, communication and operational and strategic issues. Reliance is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Reliance A/S
Reliance A/S Miscellaneous Commercial ServicesCommercial Services Reliance A/S provides business consulting services. The company also provides services to the public and initial public offering companies. It offers advices in the areas such as investor relations, corporate finance, equity research, communication and operational and strategic issues. Reliance is headquartered in Copenhagen, Denmark. | Commercial Services |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |